Glioblastoma

News Glioblastoma

• Merck: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma

  Merck announced that the Phase III CENTRICa trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). CENTRIC includes patien more

• Gene deletion causes 25 percent of breast cancers

  A new study shows that the lack of a certain gene occurs in almost 28 percent of human breast cancers, playing a role in some 60,000 breast cancer cases in the United States and 383,000 worldwide this year.Recent studies have observed loss of the gene NF1 in glioblastoma, lung and ovarian cancers, b more

• Neural Precursor Cells Induce Cell Death in Certain Brain Tumors

  Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors. Now researchers of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and Charité – Unive more

Publications Glioblastoma

• [Report] Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

  Mutations of histones in some cancers result in inhibition of enzymes that lay down epigenetic marks on chromatin. [Also see Perspective by Morgan and Shilatifard] more

• miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma

  by Soumya Alige Mahabala Rao, Arivazhagan Arimappamagan, Paritosh Pandey, Vani Santosh, Alangar Sathyaranjandas Hegde, Bangalore Ashwathnarayanara Chandramouli, Kumaravel Somasundaram Glioblastoma is one of the common types of primary brain tumors with a median survival of 12–15 months. The recep more

• Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression

  Glioblastoma multiforme is the most aggressive type of primary brain tumor. Glioblastoma growth dynamics vary widely across patients, making it difficult to accurately gauge their response to treatment. We developed a model-based metric of therapy response called Days Gained that accounts for this h more

Market studies Glioblastoma

• Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review

  Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review Summary Sophiris Bio, Inc. (Sophiris), formerly Protox Therapeutics Inc., is a biopharmaceutical company. It focuses on the research, development and commercialization of products for the treatment of urological diseases, such more

• MDxHealth SA (ONCOB) - Financial and Strategic SWOT Analysis Review

  MDxHealth SA (MDxHealth) is a publicly held molecular diagnostics company that is engaged in developing gene methylation tests for early cancer detection and treatment. The company serves physicians by developing novel molecular tests for detecting cancer. MDxHealth products include treatment produc more

• Successes and Failures for Avastin (Bevacizumab) mean Mixed News for the Blockbuster Drug in the Oncology Therapeutics Market

  Introduction Avastin (bevacizumab) is a vascular endothelial growth factor (VEGF) receptor inhibitor. It was first approved in 2004 and is used in the treatment of various cancers. At present, it is approved for the late-stage treatment of colorectal cancer, non-small cell lung cancer (NSCLC), rena more

Websites Glioblastoma